Recently, it has been shown that topical treatment with the CCR2 antagonist (JNJ17166864) reduced alveolar bone loss from bacterial infection in mice supporting a role for CCR2 in bone loss (49). This evidence concerns the gene CCR2 and bacterial infectious disease.